Lifecore Biomedical (NASDAQ:LFCR) Posts Earnings Results, Beats Estimates By $0.03 EPS

Lifecore Biomedical (NASDAQ:LFCR) issued its quarterly earnings data on Wednesday. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03, FiscalAI reports. The company had revenue of $34.17 million for the quarter, compared to the consensus estimate of $32.02 million.

Here are the key takeaways from Lifecore Biomedical’s conference call:

• Reaffirmed 2026 guidance for revenue of $120 million–$125 million and adjusted EBITDA of $20.5 million–$25 million, with stronger CDMO revenue expected in the second half, particularly in Q4.
• Contractually committed fill-finish demand from Lifecore’s largest customer is expected to double in 2027 and increase more than 200% in 2028 versus 2026, while a successful PMDA inspection supports potential expansion into Japan.
• The company added six pipeline programs during the quarter and nine year-to-date, including late-stage and commercial site-transfer opportunities; management believes 11 existing development programs could commercialize by the end of 2028.
• Second-quarter revenue fell 6.2% to $34.2 million, while six-month revenue declined 19.9% to $57.4 million; adjusted EBITDA decreased to $8.6 million in the quarter and $9.6 million for the six-month period, and the quarterly net loss widened to $6.2 million.
• Liquidity improved to approximately $38.8 million, but potential Series A preferred payments are not due until December 2028 and would require lender approval; unpaid amounts would accrue interest at 1% per month.

Lifecore Biomedical Price Performance

Shares of NASDAQ LFCR traded up $0.09 during trading on Wednesday, reaching $4.43. 75,656 shares of the stock traded hands, compared to its average volume of 239,021. The stock has a market capitalization of $166.36 million, a P/E ratio of -4.76 and a beta of 1.08. Lifecore Biomedical has a 52-week low of $3.63 and a 52-week high of $8.98. The company has a 50-day moving average of $5.04 and a 200-day moving average of $5.63.

Institutional Investors Weigh In On Lifecore Biomedical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LFCR. Quarry LP bought a new position in Lifecore Biomedical during the third quarter worth about $28,000. BNP Paribas Financial Markets lifted its stake in shares of Lifecore Biomedical by 92.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock valued at $43,000 after buying an additional 2,786 shares in the last quarter. State of Wyoming purchased a new stake in shares of Lifecore Biomedical during the 2nd quarter valued at approximately $69,000. The Manufacturers Life Insurance Company bought a new position in Lifecore Biomedical in the 2nd quarter worth approximately $88,000. Finally, Graham Capital Management L.P. purchased a new position in Lifecore Biomedical in the 4th quarter valued at approximately $111,000. 83.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on LFCR shares. Zacks Research raised shares of Lifecore Biomedical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Wall Street Zen raised Lifecore Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Barrington Research boosted their price objective on Lifecore Biomedical from $6.00 to $6.50 and gave the stock an “outperform” rating in a research report on Tuesday, June 16th. Finally, Weiss Ratings lowered Lifecore Biomedical from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.50.

About Lifecore Biomedical

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.